Document is current
Any future updates will be listed below
-
Authors
Hall-Roberts, Hazel https://orcid.org/0000-0003-0330-9604
Agarwal, Devika
Obst, Juliane
Smith, Thomas B.
Monzón-Sandoval, Jimena
Di Daniel, Elena
Webber, Caleb
James, William S.
Mead, Emma
Davis, John B.
Cowley, Sally A.
-
Funding
Funding for this research was provided by:
Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-2020DDI-OX)
Oxford Martin School, University of Oxford (LC0910-004)
Parkinson’s UK (J-1403)
Medical Research Council (MC_EX_MR/N50192X/1, MR/N013255/1, MC_PC_16034, G0900747 91070)
Wellcome Trust (090532/Z/09/Z)
Wellcome Trust (203141/Z/16/Z)
- License Information
-
More Information
Article History
Received: 28 February 2020
Accepted: 20 October 2020
First Online: 16 November 2020
Ethics approval and consent to participate
: The WT parent line BIONi010-C was generated by Bioneer from normal adult human skin fibroblasts sourced from Lonza (#CC-2511), who provide the following ethics statement: ‘These cells were isolated from donated human tissue after obtaining permission for their use in research applications by informed consent or legal authorization.’ For Fig. S5 (Additional file ), pMac differentiated from SFC840-03-03 iPSC were used. SFC840-03-03 was derived from dermal fibroblasts from a disease-free donor recruited through the Oxford Parkinson’s Disease Centre, having given signed informed consent, which included derivation of hiPSC lines from skin biopsies (Ethics Committee: National Health Service, Health Research Authority, NRES Committee South Central, Berkshire, UK (REC 10/H0505/71)).
: Not applicable.
: The authors declare that they have no competing interests.
